Upstream Bio (UPB) Competitors $20.18 -0.08 (-0.39%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock UPB vs. AKRO, MIRM, MENS, PTGX, APLS, MLTX, MTSR, SRRK, KYMR, and XENEShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include Akero Therapeutics (AKRO), Mirum Pharmaceuticals (MIRM), Jyong Biotech (MENS), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Scholar Rock (SRRK), Kymera Therapeutics (KYMR), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Upstream Bio vs. Its Competitors Akero Therapeutics Mirum Pharmaceuticals Jyong Biotech Protagonist Therapeutics Apellis Pharmaceuticals MoonLake Immunotherapeutics Metsera Scholar Rock Kymera Therapeutics Xenon Pharmaceuticals Akero Therapeutics (NASDAQ:AKRO) and Upstream Bio (NASDAQ:UPB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Do analysts prefer AKRO or UPB? Akero Therapeutics presently has a consensus target price of $81.57, suggesting a potential upside of 80.85%. Upstream Bio has a consensus target price of $56.50, suggesting a potential upside of 179.98%. Given Upstream Bio's higher possible upside, analysts plainly believe Upstream Bio is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, AKRO or UPB? Upstream Bio has higher revenue and earnings than Akero Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$2.00-22.55Upstream Bio$2.37M459.03-$62.81MN/AN/A Does the media prefer AKRO or UPB? In the previous week, Akero Therapeutics and Akero Therapeutics both had 9 articles in the media. Akero Therapeutics' average media sentiment score of 1.46 beat Upstream Bio's score of 1.05 indicating that Akero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AKRO or UPB more profitable? Akero Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -3,836.58%. Akero Therapeutics' return on equity of -15.84% beat Upstream Bio's return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.84% -14.59% Upstream Bio -3,836.58%-35.90%-26.26% SummaryAkero Therapeutics beats Upstream Bio on 5 of the 8 factors compared between the two stocks. Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.08B$3.09B$5.74B$9.79BDividend YieldN/A2.28%6.66%4.48%P/E RatioN/A21.1182.4126.45Price / Sales459.03379.56524.84106.22Price / CashN/A43.5325.7028.92Price / Book2.668.0810.626.54Net Income-$62.81M-$53.35M$3.28B$266.04M7 Day Performance20.84%-0.13%-0.38%-0.81%1 Month Performance29.86%9.28%9.96%5.98%1 Year PerformanceN/A10.93%48.53%21.93% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream Bio2.2576 of 5 stars$20.18-0.4%$56.50+180.0%N/A$1.08B$2.37M0.0038News CoveragePositive NewsGap UpAKROAkero Therapeutics3.9157 of 5 stars$47.020.0%$81.57+73.5%+67.1%$3.77BN/A-23.5830News CoveragePositive NewsMIRMMirum Pharmaceuticals3.4445 of 5 stars$72.09+0.4%$74.13+2.8%+72.4%$3.62B$429.16M-59.56140Positive NewsMENSJyong BiotechN/A$46.75-0.5%N/AN/A$3.55BN/A0.0031News CoveragePositive NewsPTGXProtagonist Therapeutics1.7182 of 5 stars$56.70-0.3%$67.20+18.5%+37.2%$3.52B$434.43M80.89120News CoveragePositive NewsAPLSApellis Pharmaceuticals4.3124 of 5 stars$27.54+0.1%$34.12+23.9%-27.6%$3.49B$781.37M-15.17770News CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.4106 of 5 stars$54.12-0.9%$74.43+37.5%+25.2%$3.48BN/A-19.492News CoveragePositive NewsMTSRMetseraN/A$32.40-0.6%$55.00+69.8%N/A$3.40BN/A0.0081News CoverageAnalyst ForecastSRRKScholar Rock4.5082 of 5 stars$33.81+1.4%$45.75+35.3%+256.1%$3.25B$33.19M-11.62140News CoveragePositive NewsKYMRKymera Therapeutics3.5118 of 5 stars$42.48+1.6%$58.76+38.4%-15.9%$3.04B$44.71M-12.27170Positive NewsXENEXenon Pharmaceuticals2.6671 of 5 stars$38.21+0.2%$53.20+39.2%-2.6%$2.95B$9.43M-10.77210News CoverageAnalyst Forecast Related Companies and Tools Related Companies AKRO Alternatives MIRM Alternatives MENS Alternatives PTGX Alternatives APLS Alternatives MLTX Alternatives MTSR Alternatives SRRK Alternatives KYMR Alternatives XENE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPB) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
